Tema Etfs LLC Makes New $926,000 Investment in Xencor, Inc. $XNCR

Tema Etfs LLC purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 60,457 shares of the biopharmaceutical company’s stock, valued at approximately $926,000. Tema Etfs LLC owned about 0.08% of Xencor at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new stake in Xencor during the 1st quarter valued at $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock worth $471,000 after acquiring an additional 3,692 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Xencor by 89.9% in the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock worth $7,732,000 after purchasing an additional 344,088 shares in the last quarter. Creative Planning increased its holdings in shares of Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,661 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Xencor by 170.9% during the second quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock valued at $2,594,000 after purchasing an additional 208,182 shares during the period.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Barclays upped their price objective on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. JPMorgan Chase & Co. restated a “neutral” rating and set a $13.00 price target (down from $18.00) on shares of Xencor in a research report on Tuesday, March 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.38.

Xencor Trading Up 2.2%

Xencor stock opened at $12.81 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. The firm has a market cap of $939.49 million, a price-to-earnings ratio of -10.33 and a beta of 0.99. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69. The firm’s 50 day moving average price is $12.01 and its two-hundred day moving average price is $13.43.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. The company had revenue of $28.24 million during the quarter, compared to the consensus estimate of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The company’s quarterly revenue was down 46.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.62) EPS. On average, research analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Transactions at Xencor

In other news, SVP Celia Eckert sold 3,244 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $36,495.00. Following the completion of the sale, the senior vice president directly owned 78,685 shares of the company’s stock, valued at $885,206.25. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 6,606 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $11.02, for a total value of $72,798.12. Following the completion of the transaction, the chief executive officer owned 546,316 shares of the company’s stock, valued at $6,020,402.32. This trade represents a 1.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 44,020 shares of company stock valued at $499,817 over the last three months. Company insiders own 4.76% of the company’s stock.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.